| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
Angiotensin III targets angiotensin type 1 (AT1) and angiotensin type 2 (AT2) receptors. It has a 30-fold higher affinity for AT2 compared with AT1 in HEK293 cells. The IC₅₀ values for AT2R and AT1R are 0.648 nM and 21.1 nM, respectively. Angiotensin III is the preferred agonist for renal AT2 receptors, which are responsible for sodium excretion into the urine. The peptide plays a crucial role in the regulation of blood pressure and fluid balance.
|
|---|---|
| ln Vitro |
The heptapeptide angiotensin III (human, mouse) functions as an endogenous agonist of the angiotensin type 2 receptor (AT2R), with IC50 values for AT2R and AT1R of 0.648 nM and 21.1 nM, respectively [1].
In vitro, angiotensin III is a potent agonist at both AT1 and AT2 receptors. It has a 30-fold higher affinity for AT2 compared with AT1 in HEK293 cells. The IC₅₀ values for AT2R and AT1R are 0.648 nM and 21.1 nM, respectively. Angiotensin III stimulates aldosterone secretion and influences vasoconstriction. The peptide's activity is typically assessed by measuring receptor activation in cell-based assays. |
| ln Vivo |
In SD rats, angiotensin III (7, 14 and 28 nmol/kg/min) increases fractional sodium excretion (FENa), fractional lithium excretion (FELi) and urine natriuresis (UNaV) [2]. Rats with elevated blood pressure are the result of angiotensin III's stimulation of sympathetic nerve activity, vasopressin production, and inhibition of baroreflex in the renin-angiotensin system [3].
In vivo, angiotensin III plays a crucial role in the regulation of blood pressure and fluid balance. It is derived from the enzymatic cleavage of angiotensin II and acts primarily on angiotensin receptors. Angiotensin III is the preferred agonist for renal AT2 receptors, which are responsible for sodium excretion. The peptide influences vasoconstriction and aldosterone secretion. However, specific in vivo efficacy studies have not been extensively reported. |
| Enzyme Assay |
In vitro enzyme/receptor binding assays for angiotensin III typically involve competition binding studies using membranes from cells expressing human AT1 or AT2 receptors. The peptide is incubated with various concentrations of radiolabeled ligand (e.g., ¹²⁵I-angiotensin II) in binding buffer. Nonspecific binding is determined in the presence of excess unlabeled angiotensin II or a specific receptor antagonist. Following incubation, bound and free ligand are separated by filtration, and bound radioactivity is measured by gamma counting. IC₅₀ values are calculated by nonlinear regression analysis.
|
| Cell Assay |
In vitro cell-based assays for angiotensin III typically employ HEK293 cells or other cell lines stably expressing human AT1 or AT2 receptors. Cells are cultured in appropriate medium and treated with various concentrations of the peptide. Receptor activation is assessed by measuring intracellular calcium mobilization (for AT1) or other downstream signaling events (e.g., cAMP modulation for AT2). EC₅₀ values are determined from concentration-response curves. The peptide's activity is compared to that of angiotensin II.
|
| Animal Protocol |
In vivo animal studies with angiotensin III have not been extensively reported. The peptide is a component of the renin-angiotensin system and plays a role in blood pressure regulation. However, specific animal studies evaluating its pharmacokinetics or efficacy have not been described in the available literature. Angiotensin II and its analogs are more commonly studied in vivo.
|
| ADME/Pharmacokinetics |
Pharmacokinetic (PK) properties of angiotensin III have not been extensively characterized. As a peptide hormone, angiotensin III is rapidly metabolized by peptidases in the circulation and tissues. The compound has a short half-life in vivo, typically in the range of minutes. It is not orally bioavailable and requires parenteral administration for in vivo studies. Specific PK parameters have not been reported.
|
| Toxicity/Toxicokinetics |
The toxicity profile of angiotensin III has not been extensively characterized. As an endogenous peptide, angiotensin III is part of the normal physiological regulation of blood pressure. However, excessive activation of angiotensin receptors can lead to hypertension and cardiovascular pathology. The compound is intended for research use only and is not approved for therapeutic applications.
|
| References |
|
| Additional Infomation |
Angiotensin III is a peptide. Angiotensin III is a heptapeptide formed by removing the N-terminal amino acid from angiotensin II via aminopeptidase A. Like angiotensin II, angiotensin III promotes aldosterone secretion and regulates renal blood flow, but its vasopressor activity is lower (approximately 40%).
Angiotensin III (human, mouse) is a research-grade heptapeptide agonist of angiotensin AT1 and AT2 receptors. It has a 30-fold higher affinity for AT2 compared with AT1 in HEK293 cells. IC₅₀ values: 0.648 nM for AT2R and 21.1 nM for AT1R. The peptide plays a role in blood pressure regulation, vasoconstriction, and aldosterone secretion. It is not an approved therapeutic drug. Molecular formula: C₄₆H₆₆N₁₂O₉; molecular weight: 931.09. Sequence: Arg-Val-Tyr-Ile-His-Pro-Phe. Synonyms include Angiotensin III and 2-8-angiotensin II. |
| Molecular Formula |
C46H66N12O9
|
|---|---|
| Molecular Weight |
931.091240000001
|
| Exact Mass |
930.508
|
| CAS # |
13602-53-4
|
| Related CAS # |
Angiotensin III, human, mouse TFA
|
| PubChem CID |
3082042
|
| Appearance |
White to off-white solid powder
|
| Density |
1.39g/cm3
|
| Index of Refraction |
1.657
|
| LogP |
3.719
|
| Hydrogen Bond Donor Count |
11
|
| Hydrogen Bond Acceptor Count |
12
|
| Rotatable Bond Count |
25
|
| Heavy Atom Count |
67
|
| Complexity |
1680
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)O)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)N
|
| InChi Key |
QMMRCKSBBNJCMR-KMZPNFOHSA-N
|
| InChi Code |
InChI=1S/C46H66N12O9/c1-5-27(4)38(57-40(61)33(21-29-15-17-31(59)18-16-29)53-42(63)37(26(2)3)56-39(60)32(47)13-9-19-51-46(48)49)43(64)54-34(23-30-24-50-25-52-30)44(65)58-20-10-14-36(58)41(62)55-35(45(66)67)22-28-11-7-6-8-12-28/h6-8,11-12,15-18,24-27,32-38,59H,5,9-10,13-14,19-23,47H2,1-4H3,(H,50,52)(H,53,63)(H,54,64)(H,55,62)(H,56,60)(H,57,61)(H,66,67)(H4,48,49,51)/t27-,32-,33-,34-,35-,36-,37-,38-/m0/s1
|
| Chemical Name |
(2S)-2-[[(2S)-1-[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~100 mg/mL (~107.40 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.0740 mL | 5.3701 mL | 10.7401 mL | |
| 5 mM | 0.2148 mL | 1.0740 mL | 2.1480 mL | |
| 10 mM | 0.1074 mL | 0.5370 mL | 1.0740 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
